Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

OCUL

OCULAR THERAPEUTIX, INC

Pharmaceutical Preparations · SIC 2834CIK 1393434Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$52.0M
Net Income FY2025
$(266.0M)
EPS (Basic, as reported)
$-1.42
Net Margin FY2025
-511.9%
ROE FY2025
-40.6%
Total Equity
$654.0M
Shares Out
220M
Business description

OCULAR THERAPEUTIX, INC — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2012–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 2 → 52 +43.6% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023⚑FY2024FY2025
Revenue2224174451586452
Cost of revenue000(2)(2)(4)(5)(5)(6)(7)
Research & development(27)(31)(37)(41)(29)(50)(53)(61)(128)(197)
Selling & marketing(7)(17)(5)(24)(27)(35)(40)(41)(42)(54)
General & administrative(11)(16)(19)(22)(23)(32)(32)(34)(61)(64)
Total operating expenses(45)(64)(61)(90)(80)(122)(130)(141)(236)(322)
Operating income(43)(62)(59)(86)(63)(78)(79)(82)(172)(270)
Interest expense(2)(2)(2)(6)(7)(7)(7)(11)(14)(12)
Other income (expense), net(1)(1)(1)(1)(93)7182(22)4
Income tax expense0000000000
Net income(45)(63)(60)(86)(156)(7)(71)(81)(194)(266)
EPS — basic———($1.91)($2.56)($0.09)($0.92)($1.01)($1.22)($1.42)
EPS — diluted———($1.91)($2.56)($0.98)($0.97)($1.02)($1.22)($1.42)
Shares outstanding — basic (M)———4561767780158187
Shares outstanding — diluted (M)———4561828386158187

Showing the latest 10 of 14 fiscal years.

  • ⚑ Weighted-average shares changed ×1.98 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.